

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/44142 A2

(51) International Patent Classification⁷: C07D

(21) International Application Number: PCT/US01/43160

(22) International Filing Date:
27 November 2001 (27.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/253,301 28 November 2000 (28.11.2000) US
60/297,814 13 June 2001 (13.06.2001) US

(71) Applicant: WYETH [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: CHILDERS, Wayne, Everett; 201 Riverwoods Drive, New Hope, PA 18938 (US). KELLY, Michael, Gerard; 790 Sandoval Place, Thousand Oaks, CA 91320 (US). ROSENZWEIG-LIPSON, Sharon, Joy; 25 Bosko Drive, East Brunswick, NJ 08816 (US).

(74) Agents: MILOWSKY, Arnold, S. et al.; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SEROTONERGIC AGENTS



(III)

(57) Abstract: Novel piperazine derivatives are provided having the formula (III) wherein R₁ is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof, which are useful as 5-HT_{1A} receptor antagonists.


SEROTONERGIC AGENTS

FIELD OF THE INVENTION

- 5 This invention relates to novel piperazine derivatives, to their use and to pharmaceutical compositions containing them. The novel compounds are useful as 5-HT_{1A} binding agents, particularly as 5-HT_{1A} receptor antagonists.

BACKGROUND

- 10 U.S. Patent No. 6,127,357 discloses compounds of the general formula (I):




(I)

and pharmaceutically acceptable acid addition salts thereof wherein:

- A is alkylene chain of 2 to 4 carbon atoms optionally substituted by one or more lower
 15 alkyl groups,
 Z is oxygen or sulfur,
 R is H or lower alkyl,
 R¹ is a mono or bicyclic aryl or heteroaryl radical,
 R² is a mono or bicyclic heteroaryl radical, and
 20 R³ is hydrogen, lower alkyl, cycloalkyl, cycloalkenyl, cycloalkyl(lower)alkyl, aryl,
 aryl(lower)alkyl, heteroaryl, heteroaryl(lower)alkyl, a group of formula -NR⁴R⁵ [where
 R⁴ is hydrogen, lower alkyl, aryl or aryl(lower)alkyl and R⁵ is hydrogen, lower alkyl,
 -CO(lower)alkyl, aryl, -Coaryl, aryl(lower)alkyl, cycloalkyl, or cycloalkyl-(lower)alkyl or
 R⁴ and R⁵ together with the nitrogen atom to which they are both attached represent
 25 a saturated hydrocyclic ring which may contain a further heteroatom], or a group of
 formula OR⁶ [where R⁶ is lower alkyl, cycloalkyl, cycloalkyl(lower)alkyl, aryl,
 aryl(lower)alkyl, heteroaryl or heteroaryl(lower)alkyl].

WO 97/03982 discloses compounds of the general formula (II):



(II)

including enantiomers and the pharmaceutically acceptable acid addition salts thereof.


5

The compounds of formula (II) fall within the disclosure of U.S. Patent No. 6,127,357 but are not specifically disclosed therein. Compounds of Formula II were taught to have potent 5-HT_{1A} antagonist activity *in vivo* when administered by the oral route.

10

DETAILED DESCRIPTION OF THE INVENTION

Novel compounds of the invention have the structural formula (III):



(III)

15


wherein R₁ is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.

Halogen, as used herein, refers to chlorine, fluorine, bromine and iodine.

20

The compounds of Formula III contain an asymmetric carbon atom. Accordingly, they may exist in different stereoisomeric forms or mixtures thereof

including racemates. In some preferred embodiments the R stereoisomer (Formula IIIa) is preferred.



Formula IIIa

5

In accordance with some embodiments of the invention, the (R) stereoisomer is in enantiomeric excess of the (S) stereoisomer. Preferably the compound is made up of a significantly greater proportion of its (R) stereoisomer than the (S) stereoisomer. In preferred embodiments the compound is made up of at least about 90% by weight of its (R) stereoisomer and about 10% by weight or less of its (S) stereoisomer. In other embodiments of the invention, the compound is made up of at least about 99% by weight of its (R) stereoisomer and about 1% by weight or less of the (S) stereoisomer, e.g. substantially free from (S)-stereoisomer, most preferably substantially pure or pure (R) stereoisomer. Preferred stereoisomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S.H., et al., Tetrahedron 33:2725 (1977); Eliel, E.L. Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); Wilen, S.H. Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel, Ed., Univ. of Notre Dame Press, Notre Dame, IN 1972).

The most preferred compounds of the invention are (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]propyl}-N-pyridin-2-yl-benzamide; and pharmaceutically acceptable acid addition salts thereof.


The pharmaceutically acceptable salts are the acid addition salts which can be formed from a compound of the above general formula and a pharmaceutically acceptable acid such as, for example, benzoic, phosphoric, sulfuric, hydrochloric,

hydrobromic, citric, maleic, malic, mandelic, mucic, nitric, fumaric, succinic, tartaric, acetic, lactic, pantoic, pantothenic, benzenesulfonic, or methanesulfonic acid. In some embodiments of the invention the preferred acid addition salt is hydrochloric acid.


5

The compounds of the present invention can be prepared by known methods from known starting materials which are available by conventional methods. For example the compounds may be prepared by the general methods disclosed in EP-A-0512755 and WO 97/03982. Accordingly this invention provides a process for
10 preparing a compound of formula (III) which comprises one of the following:

a) acylating a compound of formula (IV):




15 using an acylating agent containing the moiety




wherein R_1 is as defined herein;

or

20 b) alkylating an amide or thioamide of formula (VI)




(where R_1 is defined above) with an alkylating agent (e.g halide or tosylate) providing the group of formula (VII)




5 or

c) alkylating a compound of formula (VIII)



with a compound of formula (IX)




10

(where R_1 is as defined above and X is a leaving group)

or

d) heteroarylated a compound of formula (X)





15

(where R_1 is as defined above) with a compound providing the 2-pyridyl group;

or

e) reacting a piperazine compound of formula

5 (where R₁ is as defined above) with a fluoro compound of formula

or



f) converting a basic compound of formula (III) as defined herein to a
10 pharmaceutically acceptable acid addition salt thereof or vice versa;

or

g) resolving a racemic compound of formula (III) to give an enantiomeric excess
of the R form over the S form, or vice versa.

15

Such disclosed methods include acylating an amine of formula (IV) with a known benzoyl chloride (V) or an alternative acylating derivative thereof. Examples of acylating derivatives include the acid anhydride, imidazolides (e.g. obtained from carbonyldiimidazole), or activated esters.



20

wherein R₁ is cyano, halogen, trifluoromethyl or nitro.

Novel compounds of the present invention are potent 5-HT_{1A} binding agents which selectively bind to the 5-HT_{1A} receptor. Furthermore, the novel compounds of the invention are 5-HT_{1A} receptor antagonists when tested by standard pharmacological procedures.

In addition, the novel compounds of formula (III) are unique from previously disclosed 5HT1A receptor antagonists in that they possess a superior duration of action as a 5-HT_{1A} receptor antagonist when administered *in vivo*.

EXAMPLES

The present invention is illustrated by reference to the following example. Those skilled in the art of organic synthesis may be aware of still other synthetic routes to the invention compound. The reagents and intermediates used herein are either commercially available or prepared according to standard literature procedures.

EXAMPLE 1

(R)-4-Cyano-N-{2-[4-(2,3-Dihydro-Benzo[1,4]dioxin-5-yl)-Piperazin-1-yl]-Propyl}-N-Pyridin-2-yl-Benzamide

A solution of {(R)-2-[4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]propyl}-pyridin-2-ylamine (0.846 g, 2.38 mmol) in dichloromethane (20 mL) was treated at 0°C with the dropwise addition of a dichloromethane solution of 4-cyanobenzoyl chloride (1.1 equivalents, 2.63 mmol in 5 mL). After stirring for 16 hours the mixture was poured onto hexane (100 mL) to precipitate the titled compound as its mono- hydrochloride salt (white solid, 1.2 g, 97% yield), which was recrystallized from dichloromethane/hexane.

MS (+) 484 (M + H)⁺.

m.p. 239-240°C

[α]_D²⁵ = + 56 (c = 0.6, MeOH)


Elemental Analysis for: C₂₈H₂₉N₅O₃ • 1.0 HCl

Calculated: C, 64.67; H, 5.81; N, 13.47:


Found: C, 64.69; H, 5.93; N, 13.52:

In order to demonstrate the superior duration of action of the compounds of formula (III), Example 1 was compared to representative compounds of U.S. Patent No. 6,127,357 and WO 97/03892.

5 Representative compounds of U.S. Patent No. 6,127,357 possess a cyclohexylamide moiety and a 2-methoxyphenylpiperazine grouping. The most potent example of this general structure (and the most potent compound taught in U.S. Patent No. 6,127,357) is compound A, described as "example 3" in U.S. 6,127,357. The only other class of compounds in U.S. 6,127,357 for which data are given is that
10 which possess a cyclohexylamide moiety and a benzodioxinylpiperazine grouping ("Example 17" in U.S. 6,127,357). A small subset of this class of compounds is specifically claimed in WO97/03892, with the preferred compound being compound B ("example A1" in WO97/03892). Therefore, these two preferred examples from EP-A-0512755 and WO 97/03892 have been chosen as representatives for
15 comparison to the compounds of formula (III).



Compound A
("Example 3" from U.S. 6,127,357)



Compound B
("Example A1" from WO 97/03892)

20

EXAMPLE 2

BINDING PROFILE

Compounds were tested for binding to cloned human 5-HT_{1A} receptors stably transfected into CHO cells using [³H]8-OH-DPAT as the 5-HT_{1A} radioligand
25 (according to general procedure described in J. Dunlop et al., J. Pharmacol. Tox. Methods, **40**, 47-55 (1998)). As shown in Table 1, compounds of the present invention display high affinity for the 5HT1A receptor.

EXAMPLE 3**IN VITRO FUNCTIONAL ACTIVITY**

A clonal cell line stably transfected with the human 5-HT_{1A} receptor was utilized to determine the intrinsic activity of compounds (according to the general procedure described in J. Dunlop et al., J. Pharmacol. Tox. Methods, **40**, 47-55 (1998)). Data are provided in Table 1. As shown in Table 1, compounds of the present invention antagonized the ability of 10 nM 8-OH-DPAT to inhibit forskolin-stimulated cAMP production in a concentration-related fashion.

Table 1

Compound	5-HT _{1A} Affinity K _i (nM)	5-HT _{1A} Antagonist Activity cAMP Assay IC ₅₀ (nM)
Example 1	1.6	25
Compound A	0.96	7
Compound B	0.97	20

EXAMPLE 4**IN VIVO FUNCTIONAL ACTIVITY**

The ability of the compounds to function *in vivo* as 5-HT_{1A} antagonists was assessed in rats using a Fixed Responding Model (D. Blackman, in "Operant Conditioning: An Experimental Analysis of Behavior", J. Butcher, ed., Methuen and Co., Ltd., London). In this model rats are trained to respond (lever pressing) under a fixed-ratio 30 schedule of food presentation in order to receive a food pellet reinforcer. Administration of the 5-HT_{1A} agonist 8-OH-DPAT reduces the control response rate (assessed by administration of vehicle placebo). The 5-HT_{1A} antagonist activity of a test compound is determined by measuring its ability to antagonize this agonist-induced decrease in response rate. A full antagonist effect is considered one in which the test compound completely reverses the agonist-induced response rate, returning it to control levels. The data given in Table 2 demonstrate that a 1 mg/kg dose of the compound of Example 1 completely reverses the decrease in response rate induced

by administration of a 0.3 mg/kg dose of 8-OH-DPAT. Thus, compounds of the present invention function as 5-HT_{1A} antagonists *in vivo*.

Table 2

Response Rate (responses/second)		
Vehicle (Control)	8-OH-DPAT (0.3 mg/kg sc)	8-OH-DPAT (0.3 mg/kg sc) + Example 1 (1 mg/kg sc)
2.4 ± 0.5	0.5 ± 0.2	2.5 ± 0.2

5

EXAMPLE 5**DURATION OF ACTION *IN VIVO***

The duration of action in the Fixed Responding Model was assessed by pre-treating animals with test compound and then challenging with a 0.3 mg/kg dose of the 5-HT_{1A} agonist 8-OH-DPAT at various time intervals after the administration of test compound. All drug and vehicle administrations were made by the subcutaneous route. Doses of the test compounds selected for comparison were those which caused a ten-fold shift in the 8-OH-DPAT dose-response curve when administered 30 minutes prior to agonist. The doses selected for the duration of action comparison are listed in Table 3.

15

Table 3

Test Compound	Dose Which Shifts Agonist Dose-response Curve by 10-fold (mg/kg, sc)
Compound A (Figure 1)	0.03
Compound B (Figure 1)	0.1
Example 1	1.0

Data are presented for pre-treatment of the animals with test compound at 0.5 hours, 2 hours, and 4 hours prior to administration of a 0.3 mg/kg dose of 8-OH-DPAT. Results are normalized to control values, with 100% being the control response rate observed when vehicle is administered rather than the agonist 8-OH-DPAT.

20

Table 4

Compound	% Response Rate		
	0.5 hour pretreatment	2 hour pretreatment	4 hour pretreatment
Compound A+ 8-OH-DPAT	90 ± 3	55 ± 28	41 ± 26
Control + 8-OH-DPAT	23 ± 9	3 ± 1	3 ± 1
Compound B+ 8-OH-DPAT	100 ± 11	71 ± 12	27 ± 14
Control + 8-OH-DPAT	21 ± 9	42 ± 6	42 ± 6
Example 1 + 8-OH-DPAT	100 ± 7	118 ± 13	99 ± 16
Control + 8-OH-DPAT	29 ± 6	35 ± 10	35 ± 10

As can be seen from Table 4, all three test compounds (Compound A, B and Example 1) completely antagonize the agonist-induced decrease in responding 30 minutes after their administration, returning the response rate to control levels. However, when agonist is given 2 hours following test drug administration (Column 3), the 5-HT_{1A} antagonist effects of compounds A and B no longer return the response rate to control levels while Example 1 still displays complete 5-HT_{1A} antagonist effects. By four hours post-administration (Column 4), the 5-HT_{1A} antagonist effects of Compounds A and B are completely lost, while Example 1 continues to provide complete antagonism of the agonist-induced decrease in response rate. Thus, the duration of action of Example 1 is longer than 4 hours, while those of Compounds A and B are somewhere between 30 minutes and 2 hours.

The increased duration of action of the novel compounds of the present invention, compared to that of the classes of compounds disclosed in U.S. Patent No. 6,127,357 and WO 97/03892 is particularly advantageous in that a smaller number of doses of the compound can be administered to produce a similar therapeutic effect.

Compounds of the present invention may be used to treat a subject suffering from CNS disorders such as schizophrenia, (and other psychotic disorders such as paranoia and mano-depressive illness), Parkinson's disease and other motor

disorders, anxiety (e.g. generalized anxiety disorders, panic attacks, and obsessive compulsive disorders), depression (such as by the potentiation of serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors), Tourette's syndrome, migraine, autism, attention deficit disorders and hyperactivity disorders. Compounds of the present invention may also be useful for the treatment of sleep disorders, social phobias, pain, thermoregulatory disorders, endocrine disorders, urinary incontinence, vasospasm, stroke, eating disorders such as for example obesity, anorexia and bulimia, sexual dysfunction, and the treatment of alcohol, drug and nicotine withdrawal.

Compounds of the present invention are also useful for the treatment of cognitive dysfunction. Thus, compounds of the present invention may be useful for the treatment of cognitive dysfunction associated with mild cognitive impairment (MCI) Alzheimer's disease and other dementias including Lewy Body, vascular, and post stroke dementias. Cognitive dysfunction associated with surgical procedures, traumatic brain injury or stroke may also be treated in accordance with the present invention. Further, compounds of the present invention may be useful for the treatment of diseases in which cognitive dysfunction is a co-morbidity such as, for example, Parkinson's disease, autism and attention deficit disorders.

"Provided", as used herein with respect to providing a compound or substance covered by this invention, means either directly administering such a compound or substance, or administering a prodrug, derivative, or analog which will form an effective amount of the compound or substance within the body. Prodrugs can be prepared such as described in Design of Prodrugs, Bundgaard, H. ed., (Elsevier, New York 1985); Prodrugs as Novel Drug Delivery Systems, Higuchi, T and Stella, V. eds, (American Chemical Society, Washington, D.C. 1975); Design of Biopharmaceutical Properties through Prodrugs and Analogs, Roche, E. ed., (American Pharmaceutical Association Academy of Pharmaceutical Sciences, Washington, D.C., 1977); and Metabolic Considerations in Prodrug Design, Balant, L.P. and Doelker, E. in Burger's Medicinal Chemistry and Drug Discovery, Fifth Edition, Wolff, M., ed, Volume 1, pages 949-982, (John Wiley & Sons, Inc. 1995).


The compounds of the present invention may be administered orally or parentally, neat or in combination with conventional pharmaceutical carriers. Applicable solid carriers can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders, tablet-disintegrating agents or encapsulating materials. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets may contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidone, low melting waxes and ion exchange resins. Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration. Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either in liquid or solid composition form. Preferably, the pharmaceutical compositions containing the present compounds are in unit dosage form, e.g., as tablets or capsules. In such form, the composition is sub-divided in unit dosages containing appropriate quantities of the active ingredients. The unit dosage forms can be packaged compositions, for example, packaged powders, vials,

ampoules, prefilled syringes or sachets containing liquids. Alternatively, the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form. The therapeutically effective dosage to be used may be varied or adjusted by the physician and generally
5 ranges from 0.5 mg to 750 mg, according to the specific condition(s) being treated and the size, age and response pattern of the patient.

The present invention may be embodied in other specific forms without departing from the spirit and essential attributes thereof and accordingly, reference
10 should be made to the appended claims, rather than to the foregoing specification, as indicating the scope of the invention.

CLAIMS:

1. A compound according to formula (III):



(III)

wherein R₁ is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof.

2. A compound of Claim 1 wherein R₁ is cyano.

3. A compound which is 4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, or its pharmaceutically acceptable acid addition salts.

4. A compound which is (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide hydrochloride.

5. A compound according to any one of Claims 1 to 4 in which the R-isomer is in enantiomeric excess of the S-isomer.

6. A compound according to any one of Claims 1 to 5 which is made up of about 90% or more by weight R-isomer and about 10% or less by weight S isomer.

7. A compound according to any one of Claims 1 to 5 which is made up of about 99% by weight R-isomer and about 1% by weight S isomer.

8. A compound which is (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, or its pharmaceutically acceptable acid addition salt, substantially free of its (S) stereoisomer.

9. A compound as claimed in any one of Claims 1 to 8 which is in the form of a salt with hydrochloric acid.

5 10. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9, and a pharmaceutically acceptable carrier or excipient.

10 11. A pharmaceutical composition comprising (R)-4-Cyano-N-{2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazin-1-yl]-propyl}-N-pyridin-2-yl-benzamide, or its pharmaceutically acceptable acid addition salt, substantially free of its (S) stereoisomer, and a pharmaceutically acceptable carrier or excipient.

15 12. A method of treating a patient suffering from a CNS disorder comprising providing to said patient a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

20 13. A method for treating anxiety or depression in a patient in need thereof, comprising providing to the patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

25 14. A method for treating schizophrenia in a patient in need thereof, comprising providing to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

30 15. A method for treating memory deficits or cognitive dysfunction in a patient in need thereof, comprising providing to the patient a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

16. A method for treating alcohol, nicotine and drug withdrawal in a patient in need thereof, comprising providing to the patient a therapeutically effective amount

of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

5 17. A method for treating Parkinson's disease and motor disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

10 18. A method for treating migraine in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

15 19. A method for treating eating disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

20 20. A method for treating sexual dysfunction in a patient in need thereof, comprising administering to the patient an effective amount a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

21. A method for treating urinary incontinence in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

25 22. A method for treating stroke in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

30 23. A method for treating endocrine disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

24. A method for treating sleep disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.


5 25. A method for treating attention deficit disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.

10 26. A method for treating Tourette's syndrome, autism, social phobias, hyperactivity disorders or thermoregulatory disorders in a patient in need thereof, comprising administering to the patient an effective amount of a compound or pharmaceutically acceptable salt thereof as claimed in any one of Claims 1 to 9.


15 27. A compound as claimed in any one of claims 1 to 9 for use as a pharmaceutical.

28. A process for preparing a compound as claimed in claim 1 which comprises one of the following:

20 a) acylating a compound of formula (IV):



using an acylating agent containing the moiety




25

wherein R₁ is as defined in claim 1;

or


b) alkylating an amide or thioamide of formula (VI)



(VI)

5


(where R₁ is defined above) with an alkylating agent (e.g halide or tosylate) providing the group of formula (VII)



(VII)


10 or

c) alkylating a compound of formula (VIII)



(VIII)

15 with a compound of formula (IX)




(IX)

(where R₁ is as defined above and X is a leaving group)



or

d) heteroaryllating a compound of formula (X)

5 (where R₁ is as defined above) with a compound providing the 2-pyridyl group;

or

e) reacting a piperazine compound of formula

10 (where R₁ is as defined above) with a fluoro compound of formula

or

f) converting a basic compound of formula (III) as defined in Claim 1 to a
 15 pharmaceutically acceptable acid addition salt thereof or vice versa;

or

g) resolving a racemic compound of formula (III) to give an enantiomeric excess
 of the R form over the S form, or vice versa.

20

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/044142 A3

(51) International Patent Classification⁷: **A61K 31/44**,
C07D 405/12, A61P 25/28 // (C07D 405/12, 319:00,
213:00)

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZM, ZW.

(21) International Application Number: PCT/US01/43160

(22) International Filing Date:
27 November 2001 (27.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/253,301 28 November 2000 (28.11.2000) US
60/297,814 13 June 2001 (13.06.2001) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for all designations
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

(71) Applicant: **WYETH** [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).

(72) Inventors: **CHILDERS, Wayne, Everett**; 201 Riverwoods Drive, New Hope, PA 18938 (US). **KELLY, Michael, Gerard**; 790 Sandoval Place, Thousand Oaks, CA 91320 (US). **ROSENZWEIG-LIPSON, Sharon, Joy**; 25 Bosko Drive, East Brunswick, NJ 08816 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


(74) Agents: **MILOWSKY, Arnold, S. et al.**; Wyeth, Patent Law Department, Five Giralda Farms, Madison, NJ 07940-0874 (US).

(88) Date of publication of the international search report:
8 August 2002

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM (CNS) DISORDERS



(III)

(57) Abstract: Novel piperazine derivatives are provided having the formula (III) wherein R₁ is cyano, nitro, trifluoromethyl or halogen, or pharmaceutically acceptable acid addition salts thereof, which are useful as 5-HT_{1A} receptor antagonists.

WO 02/044142 A3

INTERNATIONAL SEARCH REPORT

National Application No

PCT/US 01/43160

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/44 C07D405/12 A61P25/28 //(C07D405/12,319:00,
213:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 127 357 A (CLIFFE IAN ANTHONY ET AL) 3 October 2000 (2000-10-03) cited in the application examples 3,5,17 ---	1,10,27
X	WO 97 03982 A (AMERICAN HOME PROD ;FENSOME ANDREW (US); KELLY MICHAEL GERARD (US)) 6 February 1997 (1997-02-06) cited in the application claims 1-3,6 --- -/--	1,10,27

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

23 May 2002

Date of mailing of the international search report

04/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Goss, I

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 01/43160

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>VAN STEEN B J ET AL: "Structure-Affinity Relationship Studies on 5-HT1A receptor Ligands: 2. Heterobicyclic Phenylpiperazines with N4-Aralkyl Substituents"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, nb. 17, 19 August 1994 (1994-08-19), pages 2761-2773, XP002055699</p> <p>ISSN: 0022-2623</p> <p>the whole document</p>	1,10,27

INTERNATIONAL SEARCH REPORT

Information on patent family members

national Application No

PCT/US 01/43160

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6127357	A	03-10-2000	AT 115566 T 15-12-1994
			AU 645681 B2 20-01-1994
			AU 1524192 A 05-11-1992
			BR 9201624 A 15-12-1992
			CA 2067929 A1 03-11-1992
			CN 1098098 A ,B 01-02-1995
			CN 1206589 A 03-02-1999
			CS 9201344 A3 14-10-1992
			DE 69200893 D1 26-01-1995
			DE 69200893 T2 13-04-1995
			DK 512755 T3 30-01-1995
			EP 0512755 A2 11-11-1992
			ES 2065133 T3 01-02-1995
			FI 921942 A 03-11-1992
			GB 2255337 A ,B 04-11-1992
			HK 1003001 A1 30-09-1998
			HU 61012 A2 30-11-1992
			HU 211148 B3 30-10-1995
			IE 921409 A1 04-11-1992
			IL 101722 A 14-05-1996
			JP 3095521 B2 03-10-2000
			JP 5170743 A 09-07-1993
			KR 203254 B1 15-06-1999
			MX 9201991 A1 01-11-1992
			SK 280133 B6 06-08-1999
			ZA 9203081 A 28-10-1993
WO 9703982	A	06-02-1997	AT 196294 T 15-09-2000
			AU 700546 B2 07-01-1999
			AU 6524996 A 18-02-1997
			BR 9609694 A 23-03-1999
			CN 1309127 A 22-08-2001
			CN 1190968 A ,B 19-08-1998
			DE 69610316 D1 19-10-2000
			DE 69610316 T2 29-03-2001
			DK 839146 T3 20-11-2000
			EP 0839146 A1 06-05-1998
			ES 2150684 T3 01-12-2000
			WO 9703982 A1 06-02-1997
			GR 3034408 T3 29-12-2000
			HU 9802447 A2 30-08-1999
			IL 122981 A 28-01-2001
			JP 11509544 T 24-08-1999
			NZ 313231 A 30-03-2001
			PT 839146 T 29-12-2000

THIS PAGE BLANK (USPTO)